Top

Published in:

01-02-2019 | Prostate Cancer | Editorial

MRI-targeted biopsies: What’s next?

Authors: Guillaume Ploussard, Alberto Briganti

Published in: World Journal of Urology | Issue 2/2019

Excerpt

The two last years have witnessed the confirmed advent of MRI and MRI-targeted biopsies in routine prostate cancer management thanks to the publication of a high level of evidence trials. MRI does better than TRUS biopsies in ruling out clinically significant disease (PROMIS trial), and MRI followed by targeted biopsies alone improves its detection (PRECISION trial) as compared with systematic biopsies [1, 2]. The question is no longer whether we should use MRI before biopsy and target the lesion if positive, but how this new information that implements our reflection on daily practice influences our treatment decision-making process. …

Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777CrossRef

Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822CrossRef

Ploussard G, Borgmann H, Briganti A et al (2018) Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies? World J Urol. https://doi.org/10.1007/s00345-018-2399-z CrossRefPubMed

Rouvière O, Puech P, Renard-Penna R et al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20:100–109CrossRefPubMed

Gold SA, Hale GR, Bloom JB et al (2018) Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer? World J Urol. https://doi.org/10.1007/s00345-018-2337-0 CrossRefPubMed

Marra G, Ploussard G, Futterer J et al (2019) Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach? World J Urol. https://doi.org/10.1007/s00345-018-02622-5 CrossRefPubMed

Cornud F, Roumiguié M, Barry de Longchamps N et al (2018) Precision Matters in MR imaging-targeted prostate biopsies: evidence from a prospective study of cognitive and elastic fusion registration transrectal biopsies. Radiology 287:534–554CrossRefPubMed

Wysock JS, Rosenkrantz AB, Huang WC et al (2014) A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. Eur Urol 66:343–351CrossRef

Covin B, Roumiguié M, Quintyn-Ranty ML et al (2018) Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies. World J Urol. https://doi.org/10.1007/s00345-018-2459-4 CrossRefPubMed

10.

Annoot A, Olivier J, Valtille P et al (2018) Extra-target low-risk prostate cancer: implications for focal high-intensity focused ultrasound of clinically significant prostate cancer. World J Urol. https://doi.org/10.1007/s00345-018-2442-0 CrossRefPubMed

11.

Olivier J, Kasivisvanathan V, Drumez E et al (2018) Low-risk prostate cancer selected for active surveillance with negative MRI at entry: can repeat biopsies at 1 year be avoided? A pilot study. World J Urol. https://doi.org/10.1007/s00345-018-2420-6 CrossRefPubMed

12.

Dell’Oglio P, Stabile A, Dias BH et al (2018) Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy. World J Urol. https://doi.org/10.1007/s00345-018-2360-1 CrossRefPubMed

13.

Gandaglia G, Ploussard G, Valerio M et al (2018) A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies. Eur Urol 5:64. https://doi.org/10.1016/j.eururo.2018.10.012 CrossRef

Title: MRI-targeted biopsies: What’s next?
Authors: Guillaume Ploussard
Alberto Briganti
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Published in: World Journal of Urology / Issue 2/2019
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02659-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

MRI-targeted biopsies: What’s next?

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2019

Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis

Safe transition from extracorporeal to intracorporeal urinary diversion following robot-assisted cystectomy: a recipe for reducing operative time, blood loss and complication rates

Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms—outcomes from a network meta-analysis

Increased amount and duration of tea consumption may be associated with decreased risk of renal stone disease

Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?

Defining the target prior to prostate fusion biopsy: the effect of MRI reporting on cancer detection